CLECL1

Last update 08 May 2025

Basic Info

Synonyms

C-type lectin like 1, C-type lectin-like domain family 1, CLECL1

+ [4]

Introduction

May function in mediating immune cell-cell interactions. May act as a T-cell costimulatory molecule, enhancing anti-CD3-induced proliferation. May play a role in the interaction of dendritic cells with T-cells and the cells of the adaptive immune response.

100 Clinical Results associated with CLECL1

100 Translational Medicine associated with CLECL1

0 Patents (Medical) associated with CLECL1

Literatures (Medical) associated with CLECL1

04 Mar 2025·Clinical Kidney Journal

Detection and prognostic relevance of PLA2R epitopes in idiopathic membranous nephropathy: a simultaneous quantitative multiplex suspension array detection method

Article

Author: Du, Yuanyuan ; Kao, Shangbin ; Zhao, Xueqin ; Jin, Juan ; Qin, Yuan ; Huang, Biao ; Zheng, Tianyu ; Zhang, Qingjuan ; He, Qiang ; Zhou, Xiumei ; Wu, Juan ; Yang, Fuzhou

ABSTRACTObjectiveThis study aimed to develop a multiplex suspension assay for the simultaneous quantitative detection of anti-cysteine-rich domain (anti-CysR)/C-type lectin domain 1 (CTLD1)/C-type lectin domain 6–8 (CTLD678)–immunoglobulin G4 (IgG4) antibodies of M-type phospholipase A2 receptor (PLA2R) in the serum samples of patients to evaluate the clinical application value of PLA2R epitope spreading in disease prognosis.MethodsCysR, CTLD1 and CTLD678 antigen domains were coupled to three types of microspheres. The optimal dilution ratio of biotinylated anti-human IgG4 was identified, and a multiplex suspension assay was evaluated in terms of linearity, sensitivity, precision, specificity and recovery rate. Lastly, the relationship between epitope spreading and the severity of idiopathic membranous nephropathy was evaluated.ResultsThe content of all three epitopes could be detected simultaneously within 2 h. The intra-assay precision ranged from 4.74% to 9.48%, and the inter-assay precision was between 5.13% and 13.92%. Specific experiments showed that the human IgA antibody did not cause a cross-reaction. The recovery rates ranged between 90% and 100%. The cut-off values of epitopes CysR, CTLD1 and CTLD678 between healthy individuals and patients were 6.30, 12.38 and 10.06 Ru/mL, respectively. Among them, the positive rates of epitopes CysR, CTLD1 and CTLD678 were 100%, 34% and 75%, respectively. In addition, Group 3 (CTLD1 response) accounted for 73% of the 12 patients who were not in remission. Meanwhile, when the concentration of CTLD1 exceeds 42.76 Ru/mL, the patient's prognosis may be poorer.ConclusionA multiplex suspension assay was developed for the simultaneous quantitative detection of anti-CysR/CTLD1/CTLD678–IgG4 antibodies. The epitope migration sequence of PLA2R molecules during disease progression may not follow a simple linear rule. Among them, the epitope CTLD1 is likely to exert the most significant influence on patient remission.

01 Jan 2025·Technology and Health Care

Role and mechanism of LINC02390 and its potential target genes, CLECL1 and CD69, in immune microenvironment of lung adenocarcinoma

Article

Author: Chen, Qitian ; Wang, Changying ; Luo, Haichao ; Chen, Ran

BACKGROUND: Targeted therapy and immunotherapy has brought new hope to patients with lung adenocarcinoma (LUAD) with their applications. However, the prognosis of LUAD patients is still unpromising. OBJECTIVE: It is particularly important to find the biomarkers that can predict the prognosis of LUAD. In our previous study, we found that patients with high expression of LINC02390 had a better prognosis. The clinical significance of LINC02390 and its potential target genes, CLECL1 and CD69, in the prognosis of LUAD and its role in the immune microenvironment were explored. METHODS: Through the survival analysis, LINC02390 and its potential target genes, CLECL1 and CD69, were identified as good prognostic factors for LUAD. According to GO and KEGG analyses, LINC02390-related genes were identified potentially involved in immune-related signaling pathways. Gene mutations and their relationship with immune cell infiltration were verified through the online cbioportal and TIMER database. RESULTS: CD69 was found to positively associate with CD8 [Formula: see text] T cells and CLECL1 was also positively associated with CD4 [Formula: see text] T cells. A high expression of CD69 in CD8 [Formula: see text] T cells was identified through the single-cell sequencing dataset GSE111894. Finally, CLECL1 and CD69 were lowly expressed in clinical tissue samples with LUAD by immunohistochemical staining. CONCLUSIONS: LINC02390 and its possible target genes, CLECL1 and CD69, may be potential targets for the immunotherapy in LUAD patients.

01 Sep 2021·European Journal of HaematologyQ3 · MEDICINE

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients

Q3 · MEDICINE

Article

Author: Nemeth, Michael J. ; Ossenkoppele, Gert J. ; Maguire, Orla ; Kwidama, Zinia W. ; Griffiths, Elizabeth A. ; Ma, Connie Y. ; Sumiyoshi, Teiko ; Janssen, Jeroen J. W. M. ; Snel, Alexander N. ; Pourmohamad, Tony ; Venniker‐Punt, Bianca ; Smit, Linda ; Gjertsen, Bjørn T. ; Manz, Markus G. ; van Kuijk, Bo J. ; Green, Cherie ; Logan, Aaron C. ; Ngai, Lok Lam ; Cooper, James ; Robert, Alberto ; Cloos, Jacqueline ; Do, An D.

AbstractObjectivesThis study aims to retrospectively assess C‐lectin‐like molecule 1 (CLL‐1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL‐1 bimodal associations with leukemia and patient‐specific characteristics.MethodsFlow cytometry assays were performed to assess the deeper immunophenotyping of CLL‐1 bimodality. Cytogenetic analysis was performed to characterize the gene mutation on CLL‐1‐negative subpopulation of CLL‐1 bimodal AML samples.ResultsThe frequency of a bimodal pattern of CLL‐1 expression of CD34+ blasts ranged from 8% to 65% in the different cohorts. Bimodal CLL‐1 expression was most prevalent in patients with MDS‐related AML (P = .011), ELN adverse risk (P = .002), NPM1 wild type (WT, P = .049), FLT3 WT (P = .035), and relatively low percentages of leukemia‐associated immunophenotypes (P = .006). Additional immunophenotyping analysis revealed the CLL‐1− subpopulation may consist of pre‐B cells, immature myeloblasts, and hematopoietic stem cells. Furthermore, (pre)‐leukemic mutations were detected in both CLL‐1+ and CLL‐1− subfractions of bimodal samples (N = 3).ConclusionsC‐lectin‐like molecule 1 bimodality occurs in about 25% of AML patients and the CLL‐1− cell population still contains malignant cells, hence it may potentially limit the effectiveness of CLL‐1‐targeted therapies and warrant further investigation.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CLECL1

Basic Info

Related

Analysis